‘Mounjaro’ and the New Weight Loss Wave in Kashmir: A Clinical Reality Check

Credit By: DR MUZAFFAR AHMED MIR

• Comments 0
• 05 May 2026

Share

Share

WhatsApp Facebook Twitter Copy Link Close

As demand rises for the diabetes drug repurposed for weight loss, Kashmir must separate medical promise from social-media hype, and treatment from trend

HEALTH WATCH

A new word has entered drawing-room conversation, clinic waiting rooms and social media feeds in Kashmir: Mounjaro. For some, it is the latest medical miracle. For others, it is a symbol of a culture increasingly impatient with slow, disciplined weight loss. In whispered recommendations between relatives, in online searches late at night, and in the rising curiosity of young professionals anxious about appearance and health alike, this injectable drug has begun to acquire an aura larger than medicine itself. That is precisely why Kashmir needs a clinical reality check.

Mounjaro, the brand name for tirzepatide, is not a beauty product, not a casual slimming shortcut, and certainly not a harmless trend to be adopted because a friend, celebrity or influencer claims it “melts fat.” It is a serious prescription medicine developed originally for type 2 diabetes, though globally it has also attracted enormous attention for its remarkable effect on body weight. In many people, it does lead to substantial weight reduction. But the public conversation around it is racing ahead of medical understanding, affordability, regulation, and responsible use.

Kashmir is not immune to the obesity transition. For years, our public health anxieties were dominated by infectious disease, poor maternal health, malnutrition and inadequate access to specialist care. Those concerns remain. Yet alongside them has emerged a quieter epidemic: increasing rates of overweight, obesity, diabetes, fatty liver disease, hypertension, sleep disorders and sedentary living, particularly in urban and semi-urban populations. Longer winters, reduced physical activity, greater dependence on cars, changing food habits, processed foods, stress, poor sleep, and screen-heavy lifestyles have all played their part.

In that setting, it is unsurprising that a drug associated with dramatic weight loss would trigger excitement. Clinical trials have shown that tirzepatide can produce weight reductions that would once have seemed unrealistic outside bariatric surgery. In large international studies, participants without diabetes who were overweight or obese lost, on average, roughly 15 to 21 per cent of body weight over about 72 weeks, depending on the dose. These are not cosmetic changes. They can alter blood sugar, blood pressure, mobility, sleep apnea risk and overall metabolic health. That is the scientific basis for the buzz. The drug is not fake hype. It is medically significant. But significance is not the same as simplicity.

Tirzepatide works by acting on hormonal pathways linked to appetite, insulin response and digestion. It belongs to a new class of medicines that mimic and amplify the body’s own metabolic signals. In plain terms, it helps many patients feel less hungry, eat less, and regulate blood sugar better. That sounds straightforward. Yet the body is not a machine with a single switch. Altering appetite and gastric emptying can come with consequences, and these consequences are not minor for everyone.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite and indigestion. Some patients tolerate these well; others struggle enough to stop treatment. There are also more serious concerns that require physician oversight, including the risks of pancreatitis, gallbladder disease, dehydration-related kidney problems, and danger in certain high-risk groups.

It is generally not appropriate for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. It is also not a casual choice during pregnancy, and it must be used cautiously in people with significant gastrointestinal disease. This is why the growing temptation to treat Mounjaro as a fashionable anti-fat injection is deeply troubling.

In Kashmir, self-medication is not a fringe habit. Antibiotics, painkillers, steroids and sedatives have all, at different times, slipped too easily into informal circulation through hearsay or partial advice. If anti-obesity injections now enter that same ecosystem of half-information and social pressure, the consequences could be serious. A young woman preparing for a wedding, a middle-aged businessman worried about diabetes, or a college student struggling with body image may all approach the same drug for very different reasons. Yet not all of them need it, qualify for it, or can safely use it.

This is where medicine must draw a line that society often refuses to draw.

Not every person who wants to lose weight is a candidate for pharmacological weight-loss therapy. Clinical obesity is not defined by aesthetics alone. It is assessed through measures such as body mass index, waist circumference, associated illnesses, metabolic risk and prior response to structured lifestyle measures. The goal should not be to medicalise every fuller body, but to treat genuine disease with evidence-based tools.

Equally important, obesity itself should neither be mocked nor trivialised. For too long, people living with obesity have been subjected to moral lectures disguised as health advice: eat less, move more, try harder. Real life is more complicated. Genetics, endocrine conditions, stress, depression, sleep deprivation, food environment, medication use, and socioeconomic constraints all shape body weight. A clinically supervised drug like tirzepatide may be life-changing for some patients. That should be acknowledged without shame.

But the miracle narrative must still be resisted.

First, Mounjaro is expensive. In India, advanced metabolic drugs remain out of reach for large sections of the population. That raises an ethical question in Kashmir’s healthcare landscape: are we building a culture in which only the affluent can access modern obesity treatment, while public hospitals continue to struggle with basics? There is nothing wrong with innovation, but public conversation should not become so dazzled by premium medications that we neglect prevention, primary care screening, nutrition counselling and diabetes control at the community level.

Second, availability and regulatory clarity matter. In India, tirzepatide has drawn attention mainly through its diabetes indication, while the global fame around weight-loss use has often outpaced local public understanding. Off-label use may happen in real-world medicine, but it requires professional judgment, informed consent and close monitoring. It should never be normalised through beauty talk, social pressure or retail enthusiasm.

Third, weight often returns when treatment stops, especially if lifestyle change has not accompanied the medication. This is one of the least glamorous truths in the new weight-loss era. Patients need honest counselling: these drugs are often part of long-term chronic disease management, not a short cosmetic detour before Eid, a wedding or a holiday. If people begin them with unrealistic expectations, disappointment and rebound may follow.

There is also a specifically Kashmiri dimension to this debate. Ours is a society where appearance carries emotional and social weight, especially for women, yet where men too increasingly face pressures around fitness, productivity and visible vitality. Add to that our food culture — rich hospitality, wazwan excess at social events, winter comfort eating, sweetened noon chai habits in some households, and growing dependence on convenience foods — and one gets a complex public health picture. The answer cannot be humiliation. Nor can it be a syringe-first approach.

What Kashmir needs is a mature obesity conversation.

That means accepting four truths at once.

• One: obesity is a real medical condition with serious consequences, not merely a failure of will.
• Two: modern anti-obesity drugs such as tirzepatide represent an important scientific advance and should not be dismissed out of ignorance.
• Three: these drugs are not risk-free, not suitable for everyone, and not a substitute for clinical evaluation.
• Four: no medicine, however powerful, can replace a healthier social environment.

That social environment begins with schools that value physical activity, urban planning that permits walking, workplaces that do not glorify sedentary exhaustion, and healthcare systems that screen early for diabetes and metabolic disease. It includes better public awareness about nutrition, realistic body goals, sleep hygiene and mental health. It also requires doctors in Kashmir to communicate more clearly with patients: not merely prescribing or refusing, but explaining.

For clinicians, the Mounjaro wave is a test of professionalism. They must resist both extremes — the cynical dismissal of every patient asking about weight-loss drugs, and the irresponsible rush to cash in on demand. Proper selection, screening, follow-up, side-effect counselling and expectation management are essential. For patients, the responsibility is equally clear: do not seek this medicine from unverified channels, do not hide medical history, and do not confuse internet testimonials with medical suitability.

For newspapers, too, there is a duty. We should neither sensationalise the drug as a miracle nor demonise it as vanity medicine. Journalism should place it where it belongs: within the wider crisis of metabolic health, commercialised wellness, unequal access to healthcare and the growing collision between medicine and body-image culture.

Mounjaro may indeed prove transformative for a subset of Kashmiri patients living with obesity and diabetes. Used appropriately, it can reduce disease burden, improve quality of life and help shift obesity treatment from blame to biology. Used carelessly, it can become one more example of how medical advances are distorted by market forces, misinformation and social anxiety.

The real question before Kashmir, then, is not whether this drug works. For many patients, evidence suggests that it does. The real question is whether we, as a society, are prepared to treat weight as a matter of health rather than gossip, medicine as a matter of science rather than trend, and patients as human beings rather than before-and-after photographs.

Until that shift happens, every new injection will arrive wrapped in fantasy. And every fantasy, if left unchecked, risks becoming a public health problem of its own.

(The Author is a Registered medical practitioner and RK Health Columnist. Feedback: mir.muzaffar@yahoo.com)